Characterization of the Purified Recombinant Adenovirus for Viral Genome Structure by Restriction Enzyme Digestions

2019 ◽  
Vol 2019 (12) ◽  
pp. pdb.prot095554 ◽  
Author(s):  
Qin Su ◽  
Miguel Sena-Esteves ◽  
Guangping Gao
Keyword(s):  
Restriction Enzyme ◽  
Viral Genome ◽  
Recombinant Adenovirus ◽  
Genome Structure

Targeting IDH Mutations in AML: Wielding the Double-edged Sword of Differentiation

2020 ◽  
Vol 20 (7) ◽  
pp. 490-500 ◽  
Author(s):  
Justin S. Becker ◽  
Amir T. Fathi
Keyword(s):  
Genome Structure ◽  
Cellular Metabolism ◽  
Standard Of Care ◽  
Competitive Inhibitor ◽  
Driver Mutations ◽  
New Class ◽  
Regulatory Enzymes ◽  
Idh Mutations ◽  
Genomic Characterization

The genomic characterization of acute myeloid leukemia (AML) by DNA sequencing has illuminated subclasses of the disease, with distinct driver mutations, that might be responsive to targeted therapies. Approximately 15-23% of AML genomes harbor mutations in one of two isoforms of isocitrate dehydrogenase (IDH1 or IDH2). These enzymes are constitutive mediators of basic cellular metabolism, but their mutated forms in cancer synthesize an abnormal metabolite, 2- hydroxyglutarate, that in turn acts as a competitive inhibitor of multiple gene regulatory enzymes. As a result, leukemic IDH mutations cause changes in genome structure and gene activity, culminating in an arrest of normal myeloid differentiation. These discoveries have motivated the development of a new class of selective small molecules with the ability to inhibit the mutant IDH enzymes while sparing normal cellular metabolism. These agents have shown promising anti-leukemic activity in animal models and early clinical trials, and are now entering Phase 3 study. This review will focus on the growing preclinical and clinical data evaluating IDH inhibitors for the treatment of IDH-mutated AML. These data suggest that inducing cellular differentiation is central to the mechanism of clinical efficacy for IDH inhibitors, while also mediating toxicity for patients who experience IDH Differentiation Syndrome. Ongoing trials are studying the efficacy of IDH inhibitors in combination with other AML therapies, both to evaluate potential synergistic combinations as well as to identify the appropriate place for IDH inhibitors within existing standard-of-care regimens.

Development of a recombinant adenovirus vector production system free of replication-competent adenovirus by utilizing a packaging size limit of the viral genome

2011 ◽  
Vol 158 (1-2) ◽  
pp. 154-160 ◽  
Author(s):  
Takayuki Suzuki ◽  
Tomomi Sasaki ◽  
Koyori Yano ◽  
Fuminori Sakurai ◽  
Kenji Kawabata ◽  
...  
Keyword(s):  
Production System ◽  
Viral Genome ◽  
Recombinant Adenovirus ◽  
Adenovirus Vector ◽  
Size Limit ◽  
Recombinant Adenovirus Vector

Viral Genome Structure

1985 ◽  
pp. 57-81 ◽  
Author(s):  
Robert H. Symons
Keyword(s):  
Viral Genome ◽  
Genome Structure

Characterization of Trypanosoma cruzi isolates from Paraguay, using restriction enzyme analysis of kinetoplast DNA

1992 ◽  
Vol 86 (3) ◽  
pp. 231-237 ◽  
Author(s):  
T. Mimori ◽  
M. Maldonado ◽  
M. Samudio ◽  
A. Rojas De Arias ◽  
R. Moreno ◽  
...  
Keyword(s):  
Trypanosoma Cruzi ◽  
Restriction Enzyme ◽  
Enzyme Analysis ◽  
Restriction Enzyme Analysis ◽  
Kinetoplast Dna

Pharmacotherapy for SARS-CoV-2 and Seizures for drug repurposing presumed on Mechanistic Targets

2021 ◽  
Vol 14 ◽  
Author(s):  
Divya Goel ◽  
Ankit Srivastava ◽  
Ángel Aledo-Serrano ◽  
Anuja Krishnan ◽  
Divya Vohora
Keyword(s):  
Valproic Acid ◽  
Viral Genome ◽  
Drug Targeting ◽  
Literature Search ◽  
Genome Structure ◽  
Drug Repurposing ◽  
Drug Candidate ◽  
Atypical Pneumonia ◽  
Comparative Toxicogenomics Database ◽  
Indirect Association

Background: The currently circulating novel SARS-CoV-2 coronavirus disease (COVID-19) has brought the whole world to a standstill. Recent studies have deciphered the viral genome structure, epidemiology and are in the process of unveiling multiple mechanisms of pathogenesis. Apart from atypical pneumonia and lung disease manifestations, this disease has also been found to be associated with neurological symptoms, which include dizziness, headache, stroke, or seizures, among others. However, a possible direct or indirect association between SARS-CoV-2 and seizures is still not clear. In any manner, it may be of interest to analyze the drugs being used for viral infection in the background of epilepsy or vice versa. Objective: To identify the most credible drug candidate for COVID-19 in persons with epilepsy or COVID-19 patients experiencing seizures. Methods: A literature search for original and review articles was performed, and further, the Comparative Toxicogenomics Database was used to unearth the most credible drug candidate. Results: Our search based on common mechanistic targets affecting SARS-CoV-2 and seizures revealed ivermectin, dexamethasone, anakinra, and tocilizumab for protection against both COVID-19 and seizures. Amongst the antiseizure medications, we found valproic acid as the most probable pharmacotherapy for COVID-19 patients experiencing seizures. Conclusion: These findings would hopefully provide the basis for initiating further studies on the pathogenesis and drug targeting strategies for this emerging infection accompanied with seizures or in people with epilepsy.

scholarly journals Characterization of the distinct orthotopic bone-forming activity of 14 BMPs using recombinant adenovirus-mediated gene delivery

Gene Therapy ◽  
2004 ◽  
Vol 11 (17) ◽  
pp. 1312-1320 ◽  
Author(s):  
Q Kang ◽  
M H Sun ◽  
H Cheng ◽  
Y Peng ◽  
A G Montag ◽  
...  
Keyword(s):  
Gene Delivery ◽  
Recombinant Adenovirus

Characterization of a rearrangement in viral DNA: Mapping of the circular simian virus 40-like DNA containing a triplication of a specific one-third of the viral genome

1974 ◽  
Vol 87 (2) ◽  
pp. 289-301 ◽  
Author(s):  
George Khoury ◽  
George C. Fareed ◽  
Karen Berry ◽  
Malcolm A. Martin ◽  
Theresa N.H. Lee ◽  
...  
Keyword(s):  
Viral Genome ◽  
Simian Virus 40 ◽  
Simian Virus ◽  
Viral Dna ◽  
Dna Mapping
Sign in / Sign up

Export Citation Format

Share Document